ArticlePLoS medicine2017
Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines.
Abstract read
In one paragraph
Article in PLoS medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed.
- Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial.Lancet (London, England) · 2019Trial
- Antimicrobial Resistance in Neisseria gonorrhoeae: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting.Sexually transmitted diseases · 2019Trial
- Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae.Antimicrobial agents and chemotherapy · 2018Trial
- Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Trial
- Antigonococcal Activity and Cytotoxicity Screening of Three Ziziphus Species Indigenous to South Africa.Chemistry & biodiversity · 2026Article
- Structure-Activity Relationship Studies for 1,3,4-Thiadiazole-Based Bacterial Carbonic Anhydrase Inhibitors withJournal of medicinal chemistry · 2026Article
- Thiazoplanomicin, a new thiazolyl peptide antibiotic from the leaf-litter actinomycete Actinoplanes sp. MM794L-181F6.The Journal of antibiotics · 2025Article
- Structural and functional diversity of Resistance-Nodulation-Division (RND) efflux pump transporters with implications for antimicrobial resistance.Microbiology and molecular biology reviews : MMBR · 2024Review
- Recommendations for the optimal introduction of novel antibiotics to treat uncomplicated gonorrhoea in the face of increasing antimicrobial resistance: a case study with zoliflodacin.BMC global and public health · 2024Article
- Addressing Sexually Transmitted Infections Due toMicroorganisms · 2024Review
- Antimicrobial resistance and heterogeneity of Neisseria gonorrhoeae isolated from patients attending sexually transmitted infection clinics in Lusaka, Zambia.BMC genomics · 2024Article
- The Evaluation of Teleost-Derived Antimicrobial Peptides Against Neisseria gonorrhoeae.Cureus · 2024Article
- Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conservedInfection and immunity · 2023Article
- Population-level predictors of sexually transmitted infection rate changes in Missouri: an ecological study.Archives of public health = Archives belges de sante publique · 2023Article
- Optimisation of treatments for oralBMJ open · 2022Article
- Translating diagnostics and drug delivery technologies to low-resource settings.Science translational medicine · 2022Review
- Molecular Mechanisms of Drug Resistance and Epidemiology of Multidrug-Resistant Variants ofInternational journal of molecular sciences · 2022Review
- Antimicrobial resistance of Neisseria gonorrhoeae isolated from patients attending sexually transmitted infection clinics in Urban Hospitals, Lusaka, Zambia.BMC infectious diseases · 2022Article
- A Single Amino Acid Substitution in Elongation Factor G Can Confer Low-Level Gentamicin Resistance inAntimicrobial agents and chemotherapy · 2022Article
- In Vitro Analysis of Matched Isolates from Localized and Disseminated Gonococcal Infections Suggests That Opa Expression Impacts Clinical Outcome.Pathogens (Basel, Switzerland) · 2022Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Emilie AlirolGlobal Antibiotics Research and Development Partnership (GARDP), Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.ORCID http://orcid.org/0000-0001-8691-3991
Teodora E WiWorld Health Organization (WHO), Geneva, Switzerland.ORCID http://orcid.org/0000-0002-7640-9166
Manju BalaRegional STD Teaching, Training & Research Centre, VMMC and Safdarjung Hospital, New Delhi, India.
Maria Luiza BazzoFederal University of Santa Catarina, Florianópolis, Brazil.
Xiang-Sheng ChenNational Center for STD Control, Chinese Academy of Medical Sciences & Peking Union Medical College Institute of Dermatology, Nanjing, China.
Carolyn DealSTD Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), Rockville, Maryland, United States of America.
Jo-Anne R DillonUniversity of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Ranmini KularatneCentre for HIV & Sexually Transmitted Infections, National Institute for Communicable Diseases, Johannesburg, South Africa.
Jutta HeimGlobal Antibiotics Research and Development Partnership (GARDP), Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.
Rob Hooft van HuijsduijnenGlobal Antibiotics Research and Development Partnership (GARDP), Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.ORCID http://orcid.org/0000-0002-2261-9424
Edward W HookUniversity of Alabama, Birmingham, Alabama, United States of America.
Monica M LahraWorld Health Organization Collaborating Centre for Sexually Transmitted Diseases, South Eastern Area Laboratory Services, The Prince of Wales Hospital, Sydney, Australia.
David A LewisWestern Sydney Sexual Health Centre, Parramatta, NSW, Australia, and Marie Bashir Institute for Infectious Diseases and Biosecurity & Sydney Medical School-Westmead, University of Sydney, Westmead, Australia.
Francis NdowaSkin & GU Medicine Clinic, Harare, Zimbabwe.
William M ShaferDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, United States of America, and Laboratories of Bacterial Pathogenesis, VA Medical Center, Decatur, Georgia, United States of America.
Liz TaylerWorld Health Organization (WHO), Geneva, Switzerland.ORCID http://orcid.org/0000-0001-7533-613X
Kimberly WorkowskiDepartment of Medicine, Division of Infectious Diseases, Emory University, Atlanta, Georgia, United States of America.ORCID http://orcid.org/0000-0002-9918-9493
Magnus UnemoWorld Health Organization Collaborating Centre for Gonorrhoea and other STIs, Örebro University, Örebro, Sweden.
Manica BalasegaramGlobal Antibiotics Research and Development Partnership (GARDP), Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.ORCID http://orcid.org/0000-0002-2091-6660
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emilie Alirol and colleagues discuss the development of new treatments for gonorrhea.
Indexed as
Drug Resistance, BacterialAnti-Bacterial AgentsGonorrheaNeisseria gonorrhoeaeResearchAnti-Bacterial Agents
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC0
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.